patients with T2M show higher rates of recurrence and mortality. 4 Additionally, a prediabetic state with impaired glucose tolerance is often detected in stroke patients, 5 while deficient ischemia-induced neovascularization is also found in T2M patients. 6 Collectively, these data suggest that there is a close association between T2M
and stroke.
Unfortunately, there is a lack of efficient chemoprevention and chemotherapy for stroke in individuals with T2M despite there being a variety of medication options available for T2M treatment. 5 Among drugs in clinical use, linagliptin is characterized by its inhibition of dipeptidyl peptidase-4 (DPP-4), 7 which is responsible for the rapid degradation of incretin hormones (eg, glucagonlike peptide-1, GLP-1). 8 Linagliptin exhibits clinically meaningful improvements in glycemic control with an excellent safety profile. 9 Recently, both preclinical and clinical studies have demonstrated beneficial effects of linagliptin in counteracting stroke among diabetic patients. 10, 11 Based on these results, DPP-4 inhibitors may provide a great advantage in decreasing the risk of developing severe cerebral injuries after stroke as well as minimizing the damages of recurrent stroke in diabetes patients. 5 However, to the best of our knowledge, there has been little reported about the mechanism of action underlying the protective effect of DPP-4
inhibitors.
According to previous studies, it has been indicated that endothelial dysfunction is the key contributor to stroke. 12, 13 One characteristic feature of diabetes, hyperglycemia, is a major causal factor in the impairment of endothelial function. 14, 15 Among the molecular markers of endothelial dysfunction, vascular endothelial growth factor (VEGF) is the essential mediator of neovascularization in response to hypoxia. 6, 16 The endothelial nitric oxide synthase (eNOS) also plays a major role which is evidenced by the fact that decreased nitric oxide (NO) production significantly contributes to endothelial dysfunction in diabetes. [17] [18] [19] Although existing evidence suggests that diabetes attenuates the production of VEGF and NO, 20 the molecular basis underlying the association between the hyperglycemic state and endothelial dysfunction is still unclear.
This study was designed to investigate the protective effects of DPP-4 inhibitors against injuries induced by stroke-mimic conditions, for example, hypoxic and hyperglycemic conditions, in rat brain microvascular endothelial cells (rBMVECs) as well as to gain insight into the molecular mechanism. We utilized an in vitro cell model mimicking stroke states to evaluate the influence of hypoxia and high glucose on cell proliferation, migration, and expression of selected molecular markers. We also examined the protective effects of DPP-4 inhibitors (linagliptin and berberine) on these modeled cells. Our results indicate that DPP-4 inhibition can protect against impaired cell proliferation and migration by hypoxic/high-glucose induction in rBMVECs, which may have been achieved by increasing the production of SIRT1 as well as downstream factors, for example, hypoxia inducible factor 1α (HIF-1α), eNOS, and VEGF. 
| MATERIAL S AND ME THODS

| Immunofluorescent staining
Immunofluorescence staining was performed according to previously reported methods. 21 In brief, cells were fixed in 4% paraformaldehyde for 10 minutes, and then washed and blocked with 1% bovine serum albumin for 1 hour. The cells were incubated with DPP-4 primary antibody at 4°C overnight. After washing with PBS three times, the cells were then incubated with a secondary antibody for 1 hour at room temperature. After washing, the cells were mounted with antifade mounting medium plus DAPI.
| MTT assay
MTT assay was used to evaluate viability in accordance with previous reports. 22 Briefly, 20 μL 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl-2H-tetrazolium bromide (MTT) solution (5 μg/mL) was added to each well and incubated at 37°C for an additional 4 hours. After removing the supernatants, 150 μL of DMSO was added to dissolve the precipitated crystals. The absorbance was measured at 490 nm using a microplate reader.
| Transwell migration assay
Migration was assessed using transwell assay in accordance with previous reports. 23, 24 The Transwell insert was placed onto the 24-well plate, and the lower chamber was filled with 0. 
| RNA isolation and real-time PCR
Total RNA was extracted using TRIzol Reagent. After treatment with DNase, 0.5 μg RNA was then converted into cDNA using a revertAid first strand cDNA synthesis kit. Real-time PCR was carried out using the Applied Biosystems Prism 7300 sequence detection system with Maxima SYBR Green/ROX qPCR Master Mix according to the manual. The primers for GAPDH were as follows: forward primer, 5′-GGAGTCTACTGGCGTCTTCAC-3′; reverse primer, 5′-ATGAGCCCTTCCACGATGC-3′. The primers for SIRT1 were:
forward primer, 5′-TATGCTCGCCTTGCTGTG-3′; reverse primer, 5′-CAGAGATGGCTGGAACTGTC-3′. The primers for HIF1α were:
forward primer, 5′-CAGCGATGACACGGAAAC-3′; reverse primer, 5′-AGTGACTCTGGGCTTGAC-3′. The primers for eNOS were: forward primer, 5′-CTTTCGGAAGGCGTTTGAC-3′; reverse primer, 5′-AACTCTTGTGCTGCTCAGG-3′. The primers for VEGF were: forward primer, 5′-GAGTCTGTGCTCTGGGATTTG-3′; reverse primer, 5′-TCCTGCTACCTCTTTCCTCTG-3′.
| Western blots analysis
The collected rBMVECs were homogenized in a RIPA Lysis Buffer supplied with a protease inhibitor cocktail for 30 minutes on ice. After centrifugation, the supernatants were collected and the protein con- to PVDF membrane, blocked (5% milk), and incubated with primary antibodies against eNOS (1:1000), DPP-4 (1:1000), VEGF (1:1000), NIF-1α (1:1000), SIRT1 (1:1000), and GAPDH (1:2000) followed by horseradish peroxidase-conjugated secondary antibody (1:2000) .
Finally, the samples were detected using a chemiluminescence (ECL) system.
| Statistical analysis
All experiments were performed in triplicate, and the results are expressed as a mean ± SD. Data were analyzed using SPSS software. Comparisons among all groups (normal, model, and drug groups) were made using analysis of variance (ANOVA), followed by
Dunnett's test to determine the significance. Nine samples are used to calculate means and standard deviations.
| RE SULTS
| Hypoxic/high-glucose conditions increased the expression of DPP-4 protein in rBMVECs
First, we measured the expression and localization of DPP-4 protein in rBMVECs using immunofluorescence staining. As shown in Figure 1A , the cell-membrane expression of DPP-4 is much stronger than its cytoplasmic and nuclear expressions, suggesting DPP-4 is expressed and primarily localized on the surface of the rBMVECs.
To investigate the effect of a stroke-mimic state on the protein target DPP-4, rBMVECs were exposed to hypoxic/high-glucose conditions (30 mmol/L glucose for 7 days and 1% O 2 for the last 24 hours). After this, we compared the expression of DPP-4 between normal and hypoxia/high-glucose-induced rBMVECs using a Western blot analysis. As shown in Figure 1B , the diabetic state mimicking induction greatly enhanced the expression of the DPP-4
protein. According to the quantification of Western blot results, it was determined that the hypoxic/high-glucose conditions resulted in a more than 12-fold increase in DPP-4 expression ( Figure 1C ).
| Hypoxic/high-glucose conditions reduced the proliferation and migration of rBMVECs, which effects were counteracted by DPP-4 inhibitors
We examined the effect of hypoxic/high-glucose conditions on the We also examined the change in cell migration using a transwell assay. As shown in Figure 2B , hypoxic/high-glucose induction con- 
| Hypoxic/high-glucose conditions reduced the expression of VEGF and eNOS in rBMVECs, which was counteracted by DPP-4 inhibitors
As the key mediators of neovascularization, VEGF and eNOS are essential to recovery from hypoxic conditions. 6, 28 Existing evidence suggests that diabetes can impair eNOS activity and attenuate VEGF production. 20, 21, 29, 30 Because of this, we were interested in assessing the effect of DPP-4 inhibitors on the expression of these molecules. First, we evaluated the influence of hypoxic/high-glucose conditions at mRNA and protein levels. Both results from RT-PCR and Western blotting were found to be consistent, indicating that hypoxic/high-glucose induction significantly reduced the expression of VEGF and eNOS compared to the normal control ( Figure 4A,B) . 
| Hypoxic/high-glucose conditions reduced the expression of HIF-1α and SIRT1 in rBMVECs, which was counteracted by DPP-4 inhibitors
In the hypoxic setting, VEGF and eNOS expression is directly controlled by the transcription factor of hypoxia-inducible factor-1α
(HIF-1α). 6 HIF-1α is regulated precisely by hypoxia and hyperglycemia, both of which are major determinants of the complications associated with diabetes. 31 As shown in our results, hypoxic/highglucose conditions dramatically reduced the expression of HIF-1α
at both mRNA and protein levels compared to the normal control resulted in a 1.7-fold increase in the expression of HIF-1α ( Figure 5C ).
It has been reported that the stabilization of hypoxic HIF-1α requires the activity of sirtuin 1 protein (SIRT1). 32 Consequently, the Figure 5C ).
| SIRT1 inhibitor counteracts the effects of DPP4-inhibitors on rBMVECs under hypoxic/highglucose conditions
The above results suggested to us that SIRT1 might play an important role in the protective mechanism of DPP-4 inhibitors. To validate this hypothesis, we combined treatments with linagliptin/ berberine to the SIRT1 inhibitor nicotinamide, and assessed the effects on the cellular proliferation, migration, and expression of molecular targets. The doses of nicotinamide used in current work are determined on the basis of previous report, 34 and our preliminary experiments that concentration-dependent inhibitory effects on SIRT1 activity were evaluated (data not shown). Solvent DMSO was used as vehicle control. As shown in Figure 6 , combined treatment with 1 mmol/L nicotinamide significantly reduced the proliferation and migration of linagliptin/berberine-treated rBMVECs under hypoxic/high-glucose conditions, compared to treatment with linagliptin/berberine alone ( Figure 6A,B) . Moreover, combined 
| D ISCUSS I ON
In the present study, we report on the impairment of cerebrovascular endothelial cells in diabetic states, for example, hypoxic and high-glucose conditions. Diabetes mellitus (DM) is a chronic metabolic disorder characterized by hyperglycemia, 36 which can result in a variety of diabetes-related vascular complications or diseases, for example, stroke, resulting in a major public health burden. 37 Stroke is a major issue worldwide, having deleterious effects at individual, family, and societal levels. 4 Endothelial dysfunction plays an important role in the development of this disease and is related to stroke physiopathology, clinical severity, and outcome. 38 Here, we selected rat brain microvascular endothelial cells (rBMVECs) to investigate the influence of diabetic states on cell proliferation and migration.
We stimulated rBMVECs with hypoxic/high-glucose conditions by mimicking the diabetic state at a cellular level. 39 Our results indicate that hypoxic and high-glucose culturing resulted in a dramatic inhibition of the proliferative and migratory abilities of rBMVECs, confirming the relationship between diabetic states and endothelial cell dysfunction. 17, 40 In response to hypoxia, cells are able to trigger the expression of numerous adaptive genes. 41, 42 However, hyperglycemia can attenuate this adaptive response, resulting in a higher risk for stroke occurrence. 4 VEGF, an essential mediator of neovascularization, 6 is an important marker of endothelial dysfunction. The reduction in vasodilator NO, which is synthesized by eNOS, also has a close association with impaired endothelial function. 43 As expected, our results
indicate that the stroke-mimic conditions significantly decrease the expression of VEGF and eNOS.
We have also shown that two essential upstream targets, HIF-1α
and SIRT1, were also greatly affected by the induced diabetic states.
HIF-1α, a transcription factor controlled by hypoxia and hyperglycemia, 31 directly regulates the expression of VEGF and eNOS in the setting of hypoxia. 6 Most recently, Khan et al reported that the HIF-1α/VEGF pathway participates in promoting the endothelial function which stimulates neurorepair and functional recovery in in vivo stroke models. 44 Our finding that diabetic states decreased the expression of HIF-1α is in agreement with this previous study, suggesting that HIF-1α plays a fundamental role in the pathogenesis of stroke. SIRT1, an NAD-dependent deacetylase, is essential for the stabilization of hypoxic HIF-1α during hypoxia. 32 Previous studies have suggested the participation of SIRT1 in vascular endothelial functions. [45] [46] [47] However, there is little reported on the direct implications of SIRT1 in stroke. 48 Our results show that hypoxic/ high-glucose conditions greatly decreased the expression of SIRT1, confirming its association with endothelial cell dysfunction.
Currently, there is a severe lack of chemotherapy and chemoprevention for stroke among diabetic patients. 5 Recent studies have revealed that the DPP-4 inhibitor linagliptin can effectively prevent the occurrence of this disease. 5, 49 Based on these data, DPP-4 inhibition shows great promise as a treatment for stroke among individuals with diabetes. Unfortunately, the molecular basis of this mechanism remains unknown. In the present study, we observed the expression of DPP-4 protein in the membrane of rBMVECs, and the studied diabetic states dramatically enhanced the target protein pro- To the best of our knowledge, there is no other existing report that provides insight on this molecular mechanism. Hopefully, our work will facilitate future efforts in drug repurposing and indication expansion for currently available DPP-4 inhibitors. Our findings also provide a solid basis for targeted drug discovery against diabetes-associated vascular diseases.
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